Berenberg starts ‘well-positioned’ disruptor Ginkgo Bioworks with a Buy

Berenberg analyst Gaurav Goparaju initiated coverage of Ginkgo Bioworks with a Buy rating and $6 price target. Ginkgo is leveraging its platform to industrialize synthetic biology at scale across diverse end-markets and has "the only scaled horizontal platform in the space," said Goparaju. He believes Ginkgo is "well-positioned to disrupt cell programming across industries," the analyst added.